Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.43 |
| ▸ | GRM8 | O00222 | 3/20 | 0.43 |
| ▸ | GRM6 | O15303 | 3/20 | 0.43 |
| ▸ | SLC1A5 | Q15758 | 2/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.39 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21189163 | 1.00 | SLC7A5 (0.44) | SLC7A5GRM4GRM8GRM6SLC1A5 | |
| SCHEMBL21189160 | 1.00 | SLC7A5 (0.44) | SLC7A5GRM4GRM8GRM6SLC1A5 | |
| SCHEMBL29503063 | 1.00 | SLC7A5 (0.44) | SLC7A5GRM4GRM8GRM6SLC1A5 | |
| SCHEMBL21189161 | 1.00 | SLC7A5 (0.44) | SLC7A5GRM4GRM8GRM6SLC1A5 | |
| SCHEMBL21189139 | 1.00 | SLC7A5 (0.44) | SLC7A5GRM4GRM8GRM6SLC1A5 | |
| SCHEMBL21189162 | 1.00 | SLC7A5 (0.44) | SLC7A5GRM4GRM8GRM6SLC1A5 | |
| SCHEMBL21189140 | 1.00 | SLC7A5 (0.44) | SLC7A5GRM4GRM8GRM6SLC1A5 | |
| SCHEMBL23739018 | 0.90 | GRM4 (0.44) | SLC7A5GRM4GRM8GRM6SLC1A5 | |
| SCHEMBL55395 | 0.89 | GRM8 (0.42) | GRM4GRM8GRM6SLC1A5BTN3A1 | |
| SCHEMBL21755921 | 0.88 | GRM4 (0.43) | SLC7A5GRM4GRM8GRM6SLC1A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008137446-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASE | TRUSTEES OF BOSTON UNIVERSITY (US) | 2008-11-13 | — | — | WO | claimed |
| US-12364717-B2 | Compositions and methods for inhibiting seizures | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-22 | — | — | US | disclosed |
| US-12292445-B2 | Methods of selecting subjects for treatment with metabolomic modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-06 | — | — | US | disclosed |
| WO-2025038777-A2 | PROBIOTICS AND METHODS TO REDUCE APPETITE | BLOOM SCIENCE, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-4291301-B1 | NON-INVASIVE CANCER TREATMENT | SCIENTIA BIOTECH S L (ES) | 2025-01-15 | — | — | EP | disclosed |
| CN-119033822-A | Compositions and methods for inhibiting seizures | 加利福尼亚大学董事会 | 2024-11-29 | — | — | CN | disclosed |
| CN-110325196-B | Compositions and methods for inhibiting seizures | 加利福尼亚大学董事会 | 2024-08-27 | — | — | CN | disclosed |
| US-20240238350-A1 | COMPOSITIONS AND METHODS FOR INHIBITING SEIZURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-07-18 | — | — | US | disclosed |
| US-20240131352-A1 | NON-INVASIVE CANCER TREATMENT | UNIVERSITAT DE VALÈNCIA (ES) | 2024-04-25 | — | — | US | disclosed |
| EP-3558329-B1 | COMPOSITIONS AND METHODS FOR INHIBITING SEIZURES | UNIV CALIFORNIA (US) | 2024-01-31 | — | — | EP | disclosed |
| EP-3514160-A1 | NAHLSGEN OPTICAL RESOLUTION METHOD | Kyoto University (JP) | 2019-07-24 | — | — | EP | disclosed |
| EP-3368025-A1 | COMBINATION COMPRISING PTEROSTILBENE FOR THE TREATMENT OF CANCER | Fundación Universidad Católica de Valencia San Vicente Mártir (ES) | 2018-09-05 | — | — | EP | disclosed |
| US-20180214390-A1 | COMBINATION COMPRISING PTEROSTILBENE FOR THE TREATMENT OF CANCER | UNIVERSITAT DE VALÈNCIA - ESTUDI GENERAL (ES) | 2018-08-02 | — | — | US | disclosed |
| WO-2018119048-A1 | COMPOSITIONS AND METHODS FOR INHIBITING SEIZURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2017012774-A1 | COMBINATION COMPRISING PTEROSTILBENE FOR THE TREATMENT OF CANCER | FUNDACIÓN UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR (ES) | 2017-01-26 | — | — | WO | disclosed |
| US-8129557-B2 | Phosphonic acid diester derivative and method for producing thereof | Nagai, Kazuhiro (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129557-B2 | Phosphonic acid diester derivative and method for producing thereof | Nagai, Kazuhiro (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090163725-A1 | PHOSPHONIC ACID DIESTER DERIVATIVE AND METHOD FOR PRODUCING THEREOF | HIRATAKE, GOU (JP) | 2009-06-25 | — | — | US | disclosed |
| US-20090163725-A1 | PHOSPHONIC ACID DIESTER DERIVATIVE AND METHOD FOR PRODUCING THEREOF | HIRATAKE, GOU (JP) | 2009-06-25 | — | — | US | disclosed |
| WO-2008137446-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASE | TRUSTEES OF BOSTON UNIVERSITY (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214390-A1 | COMBINATION COMPRISING PTEROSTILBENE FOR THE TREATMENT OF CANCER | GSTP1, GGT1, GSTA1 | SLC7A5 866/4885GRM4 1140/4885GRM8 1178/4885 |
| US-20090163725-A1 | PHOSPHONIC ACID DIESTER DERIVATIVE AND METHOD FOR PRODUCING THEREOF | PPA1, G6PD, PHOSPHO1 | SLC7A5 3382/4885GRM4 4122/4885GRM8 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.